Newsfeeds - Spark Newswire

1 minute read

Evercore ISI Group Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $50

Today, 8:17 AM

Evercore ISI Group analyst Josh Schimmer initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Outperform rating and announces Price Target of $50.

RNA

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:17 AM

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on Nasdaq Capital Market yesterday.

AAMC

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 8:17 AM

BYSI

3 minute read

38 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 8:17 AM

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.

AAMC

1 minute read

FDA
News

Avidity Biosciences Sponsored Study Titled ‘Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients’ Posted To ClinicalTrials Websi…

By Benzinga Newsdesk

Today, 8:17 AM

https://clinicaltrials.gov/ct2/show/NCT05027269

RNA

2 minute read

Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

By Benzinga Newsdesk

Today, 8:17 AM

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its collaboration with

RNA

1 minute read

Credit Suisse Maintains Outperform on Avidity Biosciences, Lowers Price Target to $36

By Benzinga Newsdesk

Today, 8:17 AM

Credit Suisse analyst Judah Frommer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price target from $37 to $36.

RNA

1 minute read

Avidity Biosciences Q2 EPS $(0.70) Up From $(1.23) YoY, Sales $2.61M Up From $1.54M YoY

By Benzinga Newsdesk

Today, 8:17 AM

Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.70) per share. This is a 43.09 percent increase over losses of $(1.23) per share from the same period last year. The company reported $2.61 million in

RNA